IMPORTANCE: In the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) trial, there was a significant reduction in the adjudicated primary outcome among patients with stable atherosclerotic vascular disease randomized to dual pathway inhibition (rivaroxaban 2.5 mg twice daily plus aspirin 100 mg daily) vs aspirin monotherapy, but not with rivaroxaban 5 mg twice daily vs aspirin monotherapy. Whether the results are similar without adjudication is unknown. OBJECTIVE: To examine the impact of dual pathway inhibition (with rivaroxaban plus aspirin) or rivaroxaban monotherapy compared with aspirin monotherapy on investigator-reported CV events and to understand the extent of concordance between investigator-reported and centrally adjudicated clinical events. DESIGN, SETTING, AND PARTICIPANTS: This is a secondary analysis of the COMPASS trial, an international, double-blind, double-dummy, randomized clinical trial with a 3-by-2 partial factorial design that evaluated participants with stable atherosclerotic vascular disease receiving rivaroxaban plus aspirin, rivaroxaban monotherapy, or aspirin monotherapy. End points were collected by blinded site investigators and adjudicated by a blinded clinical end point committee. Data were analyzed from March 2013 through February 2017. INTERVENTIONS: Participants received dual inhibition pathway (2.5 mg rivaroxaban twice daily plus 100 mg aspirin once daily), rivaroxaban monotherapy (5 mg twice daily), or aspirin monotherapy (100 mg once daily). MAIN OUTCOMES AND MEASURES: The primary efficacy outcome was a composite of cardiovascular (CV) death, stroke, or myocardial infarction (MI). Adjudicated and investigator-reported end points were compared. RESULTS: A total of 27 395 patients (mean [SD] age, 68.2 [7.9] years; 78.0% men) were assessed, including 9152 patients randomized to dual pathway inhibition, 9117 patients randomized to rivaroxaban monotherapy, and 9126 patients randomized to aspirin monotherapy. Adjudication reduced the number of events by 10% to 15% for most end points. Among investigator-reported end points, dual pathway inhibition significantly reduced the rate of the primary efficacy outcome compared with aspirin alone (411 patients [4.5%] vs 542 patients [5.9%]; hazard ratio [HR], 0.75 [95% CI, 0.66-0.85]; P < .001), with similar reduction in adjudicated end points, (379 patients [4.1%] vs 496 patients [5.4%]; HR, 0.76 [95% CI, 0.66-0.86]; P < .001). Likewise, effects on ischemic end points were highly concordant (κ statistic = 0.94 [95% CI, 0.93-0.95] for the primary composite end point). Unlike with adjudicated outcomes, there was a significant reduction in the primary end point with rivaroxaban monotherapy vs aspirin monotherapy using investigator-reported events (477 patients [5.2%] vs 542 patients [5.9%]; HR, 0.88 [95% CI, 0.78-0.99]; P = .04) compared with adjudicated events (448 patients [4.9%] vs 496 patients [5.4%]; HR, 0.90 [95% CI, 0.79-1.03]; P = .12). CONCLUSIONS AND RELEVANCE: This secondary analysis of the COMPASS trial found that whether assessed by blinded site investigators or adjudicators, dual pathway inhibition significantly reduced CV events among patients with stable atherosclerotic disease compared with aspirin plus placebo. These findings suggest that using investigator-reported events in blinded clinical trials may be a more efficient alternative to adjudication. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01776424.

Brigham and Women's Hospital Harvard Medical School Boston Massachusetts

Cardiocenter University Hospital Kralovske Vinohrady Prague Czech Republic

Division of Cardiology Centro Studi ANMCO Florence Italy

Population Health Research Institute McMaster University and Hamilton Health Sciences Hamilton Canada

University of Edinburgh Edinburgh United Kingdom

Zobrazit více v PubMed

Pogue J, Walter SD, Yusuf S. Evaluating the benefit of event adjudication of cardiovascular outcomes in large simple RCTs. Clin Trials. 2009;6(3):239-251. doi:10.1177/1740774509105223 PubMed DOI

Granger CB, Vogel V, Cummings SR, et al. . Do we need to adjudicate major clinical events? Clin Trials. 2008;5(1):56-60. doi:10.1177/1740774507087972 PubMed DOI

Gaba P, Bhatt DL, Giugliano RP, et al. . Comparative reductions in investigator-reported and adjudicated ischemic events in REDUCE-IT. J Am Coll Cardiol. 2021;78(15):1525-1537. doi:10.1016/j.jacc.2021.08.009 PubMed DOI

Held C, White HD, Stewart RAH, et al. ; STABILITY Investigators . Characterization of cardiovascular clinical events and impact of event adjudication on the treatment effect of darapladib versus placebo in patients with stable coronary heart disease: Insights from the STABILITY trial. Am Heart J. 2019;208:65-73. doi:10.1016/j.ahj.2018.10.010 PubMed DOI

Manasco P, Bhatt DL. Evaluating the evaluators—developing evidence of quality oversight effectiveness for clinical trial monitoring: source data verification, source data review, statistical monitoring, key risk indicators, and direct measure of high risk errors. Contemp Clin Trials. 2022;117:106764. doi:10.1016/j.cct.2022.106764 PubMed DOI

Bhatt DL, Steg PG, Miller M, et al. ; REDUCE-IT Investigators . Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019;380(1):11-22. doi:10.1056/NEJMoa1812792 PubMed DOI

Steffel J, Eikelboom JW, Anand SS, Shestakovska O, Yusuf S, Fox KAA. The COMPASS Trial: net clinical benefit of low-dose rivaroxaban plus aspirin as compared with aspirin in patients with chronic vascular disease. Circulation. 2020;142(1):40-48. doi:10.1161/CIRCULATIONAHA.120.046048 PubMed DOI

Connolly SJ, Eikelboom JW, Bosch J, et al. ; COMPASS investigators . Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet. 2018;391(10117):205-218. doi:10.1016/S0140-6736(17)32458-3 PubMed DOI

Anand SS, Bosch J, Eikelboom JW, et al. ; COMPASS Investigators . Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet. 2018;391(10117):219-229. doi:10.1016/S0140-6736(17)32409-1 PubMed DOI

Bosch J, Eikelboom JW, Connolly SJ, et al. . Rationale, design and baseline characteristics of participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) Trial. Can J Cardiol. 2017;33(8):1027-1035. doi:10.1016/j.cjca.2017.06.001 PubMed DOI

Weintraub WS, Karlsberg RP, Tcheng JE, et al. ; American College of Cardiology Foundation; American Heart Association Task Force on Clinical Data Standards . ACCF/AHA 2011 key data elements and definitions of a base cardiovascular vocabulary for electronic health records: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Clinical Data Standards. Circulation. 2011;124(1):103-123. doi:10.1161/CIR.0b013e31821ccf71 PubMed DOI

Eikelboom JW, Connolly SJ, Bosch J, et al. ; COMPASS Investigators . Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med. 2017;377(14):1319-1330. doi:10.1056/NEJMoa1709118 PubMed DOI

Eikelboom JW, Bhatt DL, Fox KAA, et al. . Mortality benefit of rivaroxaban plus aspirin in patients with chronic coronary or peripheral artery disease. J Am Coll Cardiol. 2021;78(1):14-23. doi:10.1016/j.jacc.2021.04.083 PubMed DOI

Bhatt DL, Szarek M, Steg PG, et al. ; SOLOIST-WHF Trial Investigators . Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med. 2021;384(2):117-128. doi:10.1056/NEJMoa2030183 PubMed DOI

Bhatt DL, Szarek M, Pitt B, et al. ; SCORED Investigators . Sotagliflozin in patients with diabetes and chronic kidney disease. N Engl J Med. 2021;384(2):129-139. doi:10.1056/NEJMoa2030186 PubMed DOI

Godolphin PJ, Bath PM, Algra A, et al. . Cost-benefit of outcome adjudication in nine randomised stroke trials. Clin Trials. 2020;17(5):576-580. doi:10.1177/1740774520939231 PubMed DOI

Heels-Ansdell D, Saunders L, Zytaruk N, et al. ; PROTECT Investigators . Methods center adjudication costs for 5 morbidity outcomes in a thromboprophylaxis trial. Clin Res. Published online May 1, 2011. doi:10.1164/ajrccm-conference.2011.183.1_MeetingAbstracts.A1678 DOI

Felker GM, Butler J, Januzzi JL Jr, Desai AS, McMurray JJV, Solomon SD. Probabilistic readjudication of heart failure hospitalization events in the PARAGON-HF study. Circulation. 2021;143(23):2316-2318. doi:10.1161/CIRCULATIONAHA.121.054496 PubMed DOI

Pfeffer MA, Claggett B, Lewis EF, et al. . Impact of sacubitril/valsartan versus ramipril on total heart failure events in the PARADISE-MI trial. Circulation. 2022;145(1):87-89. doi:10.1161/CIRCULATIONAHA.121.057429 PubMed DOI PMC

Jering KS, Claggett B, Pfeffer MA, et al. . Prospective ARNI vs. ACE Inhibitor Trial to Determine Superiority in Reducing Heart Failure Events After Myocardial Infarction (PARADISE-MI): design and baseline characteristics. Eur J Heart Fail. 2021;23(6):1040-1048. doi:10.1002/ejhf.2191 PubMed DOI

Mahaffey KW, Harrington RA, Akkerhuis M, et al. ; PURSUIT Investigators . Systematic adjudication of myocardial infarction end-points in an international clinical trial. Curr Control Trials Cardiovasc Med. 2001;2(4):180-186. doi:10.1186/CVM-2-4-180 PubMed DOI PMC

Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II—Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II. Lancet. 1997;349(9063):1422-1428. doi:10.1016/S0140-6736(96)10172-0 PubMed DOI

Leonardi S, Branca M, Franzone A, et al. . Comparison of investigator-reported and clinical event committee-adjudicated outcome events in GLASSY. Circ Cardiovasc Qual Outcomes. 2021;14(2):e006581. doi:10.1161/CIRCOUTCOMES.120.006581 PubMed DOI

Jatene T, Harrington RA, Stone GW, et al. ; CHAMPION PHOENIX Investigators . Investigator-reported bleeding versus post hoc adjudication of bleeding: lessons from the CHAMPION PHOENIX trial. J Am Coll Cardiol. 2016;67(5):596-598. doi:10.1016/j.jacc.2015.11.027 PubMed DOI

Zobrazit více v PubMed

ClinicalTrials.gov
NCT01776424